RecruitingChickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
Eligible age
1–1.3 yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.
Sponsor: GlaxoSmithKline
You may qualify if…
- ✓ Participant's parent(s)/ Legally acceptable representatives (LAR\[s\]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiaries, return for follow-up visits).
- ✓ Written or witnessed/thumb printed informed consent obtained from the participant's parent(s)/LAR(s) prior to performance of any study-specific procedure.
- ✓ Healthy participants as established by medical history and clinical examination before entering into the study.
- ✓ A male or female between, and including, 12 to 15 months of age (i.e., from the day of 1-year birthday until the day before 16 months of age) at the time of the administration of study interventions.
- ✓ Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions:
- ✓ Participant who previously received the primary series of PCV in the first year of life with last dose at least 60 days prior to the administration of study intervention.
You may not qualify if…
- ✕ History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions including hypersensitivity to neomycin or gelatin.
- ✕ Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- ✕ Hypersensitivity to latex.
- ✕ Major congenital defects, as assessed by the investigator.
- ✕ Recurrent history of uncontrolled neurological disorders or seizures.
- ✕ History of measles, mumps, rubella, or varicella disease.
- ✕ Active untreated tuberculosis.
- ✕ Participants with bleeding disorders (e.g., thrombocytopenia or any coagulation disorder).
Where it's recruiting
Source: ClinicalTrials.gov · NCT06855160 · last updated 2026-05-29